Literature DB >> 18807044

Henoch-Schonlein Purpura with thrombocythaemia: an abnormality in Smad4 expression?

Joshua M Brostoff1, Gopinath M Ranganna, C Bernard Colaco.   

Abstract

We discuss a patient with Henoch-Schonlein Purpura (HSP) and a thrombocythaemia which was diagnosed as a coincidental Essential Thrombocythaemia. We suggest that deficiencies in Smad4 expression may allow for escape thrombocythaemia under the influence of the high levels of TGF-beta found in HSP. With normal Smad4 expression TGF-beta provides inhibition of thrombocyte proliferation. While this needs further elucidation, it could lead to a new approach to classification and management of HSP.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18807044     DOI： 10.1007/s00296-008-0720-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  4 in total

1.  Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura.

Authors:  Y H Yang; M T Huang; S C Lin; Y T Lin; M J Tsai; B L Chiang
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  Decrease of Smad4 gene expression in patients with essential thrombocythaemia may cause an escape from suppression of megakaryopoiesis by transforming growth factor-beta1.

Authors:  Hiroyuki Kuroda; Takuya Matsunaga; Takeshi Terui; Ikuta Tanaka; Rishu Takimoto; Koshi Fujikawa; Tetsuji Takayama; Junji Kato; Yasuo Hirayama; Sumio Sakamaki; Kyuhei Kohda; Yoshiro Niitsu
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

Review 3.  TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility.

Authors:  Bernhard Schmierer; Caroline S Hill
Journal:  Nat Rev Mol Cell Biol       Date:  2007-12       Impact factor: 94.444

4.  Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide.

Authors:  P R Lev; R F Marta; P Vassallu; F C Molinas
Journal:  Am J Hematol       Date:  2002-06       Impact factor: 10.047
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.